Our Pipeline
Our Pipeline
Explore our Programs
Therapeutic Programs
Program
Discovery
Preclinical
IND-Enabling
Partner Program
IMTO 4862
Acute Myeloid Leukemia (AML)
Modality I ADC
In-vivo POC I Q2, 2025
Therapeutic Programs
Discovery
Preclinical
IND-Enabling
IMTO 4862
Acute Myeloid Leukemia (AML)
Modality I ADC
In-vivo POC I Q2, 2025
Therapeutic Programs
Discovery
Preclinical
IND-Enabling
IMTO 4862
Acute Myeloid Leukemia (AML)
Modality I ADC
In-vivo POC I Q2, 2025
Discover the science behind our assets
Explore the innovation underpinning our breakthroughs—dive into the details of our cutting-edge target and antibody discovery platforms
Learn More
Discover the science behind our assets
Explore the innovation underpinning our breakthroughs—dive into the details of our cutting-edge target and antibody discovery platforms
Learn More
Discover the science behind our assets
Explore the innovation underpinning our breakthroughs—dive into the details of our cutting-edge target and antibody discovery platforms
Learn More
© Copyright 2024 Radical Bio. All rights reserved.
© Copyright 2024 Radical Bio. All rights reserved.
© Copyright 2024 Radical Bio. All rights reserved.
